Helicobacter pylori surface and enzyme targets

Helicobacter pylori surface and enzyme targets encompass a diverse array of proteins essential for the bacterium's survival, colonization, and pathogenicity within the human stomach. Key enzymatic targets include urease and carbonic anhydrase, which facilitate acid neutralization by producing ammonia and bicarbonate, respectively, allowing the pathogen to survive at low pH (Supuran, 2024; Scott et al., 2007). Surface targets primarily consist of adhesins such as BabA (blood group antigen-binding adhesin) and SabA (sialic acid-binding adhesin), which mediate high-affinity attachment to the gastric epithelium to prevent clearance (Ace Therapeutics, 2024; NIH, 2022). Additionally, virulence factors like VacA (vacuolating cytotoxin A) and CagA (cytotoxin-associated gene A) are delivered to host cells to disrupt signaling and induce chronic inflammation (MDPI, 2023). Therapeutic strategies typically involve a combination of antibiotics like clarithromycin and amoxicillin, often paired with proton pump inhibitors or bismuth salts to enhance efficacy (Frontiers in Microbiology, 2024). These targets are critical for managing infections that lead to chronic gastritis, peptic ulcers, and gastric adenocarcinoma (StatPearls, 2023).

Other names

H. pylori targetsHelicobacter pylori virulence factorsUreaseVacuolating cytotoxin A (VacA)Cytotoxin-associated gene A (CagA)Blood group antigen-binding adhesin (BabA)Sialic acid-binding adhesin (SabA)Carbonic anhydrase (HpCA)Peptide deformylaseShikimate pathway enzymesFlavodoxinHtrA protease

Inhibition of bacterial cell wall synthesis (Amoxicillin), protein synthesis (Clarithromycin), and DNA replication (Metronidazole); neutralization of gastric acid via urease and carbonic anhydrase inhibition; and disruption of bacterial adhesion to host tissues (Frontiers in Microbiology, 2024; NIH, 2023).